The Evidence-based CKD Clinic: Changing Practice with SGLT2 Inhibition
Published: 20 January 2022
-
Views:
65167
-
Likes:
7
-
Views:
65167
-
Likes:
7
-
25m 4sPart 2 The Consultation
-
11m 41sPart 3 The Follow-up
-
10m 46sPart 4 Patient Discharged
-
30m 9sPart 5 Q&A and Panel Discussion
Overview
Starting at the waiting room, then through to the consultation, follow-up and patient discharge, explore the role of SGLT2 inhibition in treating CKD, based on efficacy data.
Chair, Prof David Wheeler (University College London, UK) leads the patient-based, data-supported discussion on the renal efficacy and implementation of SGLT2 inhibitors in the treatment of CKD alongside Prof Carol Pollock and Dr Sunita Bavanandan.
After this educational symposium, delegates will:
- Recognise SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
- Understand data supporting the renal efficacy of SGLT2 inhibition in relation to the treatment and clinical outcomes of CKD
- Be able to identify the optimal time to initiate SGLT2 inhibitors in the treatment ofCKD
Target Audience
- Cardiologists
- Nephrologists
More from this programme
Part 1
The Waiting Room
1 session | |
The Waiting Room | Watch now |
Part 2
The Consultation
1 session | |
The Consultation | Watch now |
Part 3
The Follow-up
1 session | |
The Follow-up | Watch now |
Part 4
Patient Discharged
1 session | |
Patient Discharged | Watch now |
Part 5
Q&A and Panel Discussion
1 session | |
Q&A and Panel Discussion | Watch now |
Faculty Biographies

David Wheeler
David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.Professor Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, intravenous iron, sodium–glucose co-transporter 2 inhibitors and hypoxia-inducible factor stabilisers in patients with CKD.Professor Wheeler has also been involved in the development of clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-Chair between 2012 and 2019. His ongoing roles include serving as the National Specialty Lead for the National Institute of Health Research…